377 related articles for article (PubMed ID: 37454968)
1. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
Leuthardt AS; Boyle CN; Raun K; Lutz TA; John LM; Le Foll C
Eur J Pharmacol; 2023 Sep; 955():175912. PubMed ID: 37454968
[TBL] [Abstract][Full Text] [Related]
2. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
[TBL] [Abstract][Full Text] [Related]
3. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
4. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
7. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
8. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
Mayendraraj A; Rosenkilde MM; Gasbjerg LS
Peptides; 2022 May; 151():170749. PubMed ID: 35065096
[TBL] [Abstract][Full Text] [Related]
10. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.
Liskiewicz A; Khalil A; Liskiewicz D; Novikoff A; Grandl G; Maity-Kumar G; Gutgesell RM; Bakhti M; Bastidas-Ponce A; Czarnecki O; Makris K; Lickert H; Feuchtinger A; Tost M; Coupland C; Ständer L; Akindehin S; Prakash S; Abrar F; Castelino RL; He Y; Knerr PJ; Yang B; Hogendorf WFJ; Zhang S; Hofmann SM; Finan B; DiMarchi RD; Tschöp MH; Douros JD; Müller TD
Nat Metab; 2023 Dec; 5(12):2075-2085. PubMed ID: 37946085
[TBL] [Abstract][Full Text] [Related]
11. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
Wu Y; Ji T; Lv J; Wang Z
Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
[TBL] [Abstract][Full Text] [Related]
12. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
13. Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists.
Naylor J; Suckow AT; Seth A; Baker DJ; Sermadiras I; Ravn P; Howes R; Li J; Snaith MR; Coghlan MP; Hornigold DC
Biochem J; 2016 Sep; 473(18):2881-91. PubMed ID: 27422784
[TBL] [Abstract][Full Text] [Related]
14. GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys.
Lu SC; Chen M; Atangan L; Killion EA; Komorowski R; Cheng Y; Netirojjanakul C; Falsey JR; Stolina M; Dwyer D; Hale C; Stanislaus S; Hager T; Thomas VA; Harrold JM; Lloyd DJ; Véniant MM
Cell Rep Med; 2021 May; 2(5):100263. PubMed ID: 34095876
[TBL] [Abstract][Full Text] [Related]
15. The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice.
Meng Q; Chepurny OG; Leech CA; Pruekprasert N; Molnar ME; Collier JJ; Cooney RN; Holz GG
Diabetes Obes Metab; 2022 Jul; 24(7):1255-1266. PubMed ID: 35293666
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells.
Al-Zaid B; Chacko S; Ezeamuzie CI; Bünemann M; Krasel C; Karimian T; Lanzerstorfer P; Al-Sabah S
Pharmacol Res Perspect; 2022 Oct; 10(5):e01013. PubMed ID: 36177761
[TBL] [Abstract][Full Text] [Related]
17. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
18. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
19. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.
Knerr PJ; Mowery SA; Douros JD; Premdjee B; Hjøllund KR; He Y; Kruse Hansen AM; Olsen AK; Perez-Tilve D; DiMarchi RD; Finan B
Mol Metab; 2022 Sep; 63():101533. PubMed ID: 35809773
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut.
Morrow NM; Morissette A; Mulvihill EE
Peptides; 2024 Jun; 176():171200. PubMed ID: 38555054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
